Donna Yu

2.0k total citations · 1 hit paper
18 papers, 1.6k citations indexed

About

Donna Yu is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Donna Yu has authored 18 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in Donna Yu's work include Drug Transport and Resistance Mechanisms (11 papers), Estrogen and related hormone effects (6 papers) and Liver Disease Diagnosis and Treatment (3 papers). Donna Yu is often cited by papers focused on Drug Transport and Resistance Mechanisms (11 papers), Estrogen and related hormone effects (6 papers) and Liver Disease Diagnosis and Treatment (3 papers). Donna Yu collaborates with scholars based in United States and China. Donna Yu's co-authors include Barry M. Forman, Wendong Huang, Yan‐Dong Wang, Wei‐Dong Chen, Weidong Chen, Meihua Wang, Lisheng Zhang, Jia Su, Kyle M. Sousa and Taosheng Chen and has published in prestigious journals such as PLoS ONE, Hepatology and The Journal of Organic Chemistry.

In The Last Decade

Donna Yu

18 papers receiving 1.6k citations

Hit Papers

Farnesoid X receptor antagonizes nuclear factor κB in hep... 2008 2026 2014 2020 2008 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Donna Yu United States 16 858 575 546 525 286 18 1.6k
Wei‐Dong Chen China 20 741 0.9× 525 0.9× 829 1.5× 409 0.8× 307 1.1× 41 1.9k
Cindy Kunne Netherlands 25 889 1.0× 339 0.6× 513 0.9× 719 1.4× 141 0.5× 35 1.7k
Mitsunori Nomura United States 10 820 1.0× 528 0.9× 635 1.2× 639 1.2× 133 0.5× 13 1.7k
Graham P. Hayhurst United Kingdom 16 497 0.6× 495 0.9× 846 1.5× 516 1.0× 187 0.7× 19 1.9k
Philip B. Hylemon United States 22 949 1.1× 694 1.2× 772 1.4× 591 1.1× 437 1.5× 30 1.9k
Shogo Takahashi United States 25 763 0.9× 1.0k 1.8× 1.3k 2.3× 535 1.0× 287 1.0× 37 2.5k
Elizabeth C. Goode United Kingdom 7 613 0.7× 260 0.5× 436 0.8× 410 0.8× 127 0.4× 9 1.2k
Mieko Iwahashi United States 19 413 0.5× 355 0.6× 506 0.9× 395 0.8× 221 0.8× 27 1.4k
Songwen Zhang China 19 363 0.4× 552 1.0× 757 1.4× 414 0.8× 112 0.4× 35 1.9k
Chiara Degirolamo Italy 16 398 0.5× 380 0.7× 882 1.6× 542 1.0× 99 0.3× 17 1.6k

Countries citing papers authored by Donna Yu

Since Specialization
Citations

This map shows the geographic impact of Donna Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donna Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donna Yu more than expected).

Fields of papers citing papers by Donna Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donna Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donna Yu. The network helps show where Donna Yu may publish in the future.

Co-authorship network of co-authors of Donna Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Donna Yu. A scholar is included among the top collaborators of Donna Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donna Yu. Donna Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Yu, Donna, et al.. (2021). Discovery of novel modulators for the PPARα (peroxisome proliferator activated receptor α): Potential therapies for nonalcoholic fatty liver disease. Bioorganic & Medicinal Chemistry. 41. 116193–116193. 2 indexed citations
2.
Yu, Donna, Janice M. Huss, Hongzhi Li, & Barry M. Forman. (2017). Identification of novel inverse agonists of estrogen-related receptors ERRγ and ERRβ. Bioorganic & Medicinal Chemistry. 25(5). 1585–1599. 14 indexed citations
4.
Yu, Donna, et al.. (2016). Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease. Bioorganic & Medicinal Chemistry. 24(18). 3986–3993. 19 indexed citations
5.
Ding, Lili, Kyle M. Sousa, Lihua Jin, et al.. (2016). Vertical sleeve gastrectomy activates GPBAR‐1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice. Hepatology. 64(3). 760–773. 154 indexed citations
6.
Yu, Donna, Kyle M. Sousa, Daniell L. Mattern, et al.. (2015). Stereoselective synthesis, biological evaluation, and modeling of novel bile acid-derived G-protein coupled Bile acid receptor 1 (GP-BAR1, TGR5) agonists. Bioorganic & Medicinal Chemistry. 23(7). 1613–1628. 30 indexed citations
7.
Qi, Hui, Yingjie Yu, Qiqi Zhang, et al.. (2015). The G-Protein-Coupled Bile Acid Receptor Gpbar1 (TGR5) Inhibits Gastric Inflammation Through Antagonizing NF-κB Signaling Pathway. Frontiers in Pharmacology. 6. 287–287. 78 indexed citations
8.
9.
Yu, Donna, Wenwei Lin, Barry M. Forman, & Taosheng Chen. (2014). Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor. Bioorganic & Medicinal Chemistry. 22(11). 2919–2938. 30 indexed citations
10.
Lou, Guiyu, Xiaoxiao Ma, Xianghui Fu, et al.. (2014). GPBAR1/TGR5 Mediates Bile Acid-Induced Cytokine Expression in Murine Kupffer Cells. PLoS ONE. 9(4). e93567–e93567. 70 indexed citations
11.
Yu, Donna, Wenwei Lin, Taosheng Chen, & Barry M. Forman. (2013). Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery. Bioorganic & Medicinal Chemistry. 21(14). 4266–4278. 22 indexed citations
12.
Yu, Donna, Daniell L. Mattern, & Barry M. Forman. (2012). An improved synthesis of 6α-ethylchenodeoxycholic acid (6ECDCA), a potent and selective agonist for the Farnesoid X Receptor (FXR). Steroids. 77(13). 1335–1338. 18 indexed citations
13.
Wang, Yan‐Dong, Weidong Chen, Donna Yu, Barry M. Forman, & Wendong Huang. (2011). The G-Protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-κB) in mice. Hepatology. 54(4). 1421–1432. 392 indexed citations
14.
Zhang, Lisheng, Tao Li, Donna Yu, Barry M. Forman, & Wendong Huang. (2011). FXR Protects Lung from Lipopolysaccharide-Induced Acute Injury. Molecular Endocrinology. 26(1). 27–36. 32 indexed citations
15.
Chen, Wei‐Dong, Yan‐Dong Wang, Lisheng Zhang, et al.. (2009). Farnesoid X Receptor Alleviates Age-Related Proliferation Defects in Regenerating Mouse Livers by Activating Forkhead Box M1b Transcription. Hepatology. 51(3). 953–962. 98 indexed citations
16.
Wang, Yan‐Dong, Wei‐Dong Chen, Meihua Wang, et al.. (2008). Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response. Hepatology. 48(5). 1632–1643. 516 indexed citations breakdown →
17.
Yu, Donna & Barry M. Forman. (2005). Identification of an agonist ligand for estrogen-related receptors ERRβ/γ. Bioorganic & Medicinal Chemistry Letters. 15(5). 1311–1313. 63 indexed citations
18.
Yu, Donna & Barry M. Forman. (2003). Simple and Efficient Production of (Z)-4-Hydroxytamoxifen, a Potent Estrogen Receptor Modulator. The Journal of Organic Chemistry. 68(24). 9489–9491. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026